BiotechTube

PPAR alpha + atorvastatin + placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypercholesterolemia

Conditions

Hypercholesterolemia

Trial Timeline

Jul 1, 2005 → Sep 1, 2006

NCT ID
NCT00133380

About PPAR alpha + atorvastatin + placebo

PPAR alpha + atorvastatin + placebo is a phase 2 stage product being developed by Eli Lilly for Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00133380. Target conditions include Hypercholesterolemia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00133380Phase 2Completed

Competing Products

20 competing products in Hypercholesterolemia

See all competitors
ProductCompanyStageHype Score
Evacetrapib + Ezetimibe + Atorvastatin + PlaceboEli LillyPhase 3
77
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)YuhanApproved
85
Rosuvastatin+Ezetimibe + RosuvastatinYuhanApproved
85
colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and colesevelam HCl placeboDaiichi SankyoApproved
85
colesevelam HCl tablets and fenofibrate tablets + fenofibrate tablets and Welchol placebo tablets + fenofibrate tablets and Welchol placebo tabletsDaiichi SankyoApproved
85
colesevelam HCl + placeboDaiichi SankyoApproved
85
Bempedoic acid and/or its fixed-dose combination with ezetimibeDaiichi SankyoPre-clinical
23
colesevelam HCl tablets, and atorvastatin tablets + colesevelam HCl placebo tablets and atorvastatin tabletsDaiichi SankyoApproved
85
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
85
Bempedoic Acid 180Mg/Ezetimibe 10Mg TabDaiichi SankyoPre-clinical
23
Colesevelam Hydrochloride + Ezetimibe + SimvastatinDaiichi SankyoApproved
85
pravastatin tablets and Welchol tablets + pravastatin tablets and Welchol placebo tabletsDaiichi SankyoApproved
85
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
23
atrovastatinAstellas PharmaPre-clinical
23
Pitavastin 4mg + Atorvastatin 20mg + Rosuvastatin 5mgEli LillyApproved
85
Evacetrapib + PlaceboEli LillyPhase 3
77
LY3015014 + Placebo + Statin + EzetimibeEli LillyPhase 2
52
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injectionsJiangsu Hengrui MedicinePhase 1
33
SHR-1209Jiangsu Hengrui MedicinePhase 2
52
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85